Cargando…
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma
Uveal melanoma (UM) is the most common cancer of the eye in adults. Many UM patients develop metastases for which no curative treatment has been identified. Novel therapeutic approaches are therefore urgently needed. UM is characterized by mutations in the genes GNAQ and GNA11 which activate the PKC...
Autores principales: | Carita, Guillaume, Frisch-Dit-Leitz, Estelle, Dahmani, Ahmed, Raymondie, Chloé, Cassoux, Nathalie, Piperno-Neumann, Sophie, Némati, Fariba, Laurent, Cécile, De Koning, Leanne, Halilovic, Ensar, Jeay, Sebastien, Wylie, Andrew, Emery, Caroline, Roman-Roman, Sergio, Schoumacher, Marie, Decaudin, Didier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085101/ https://www.ncbi.nlm.nih.gov/pubmed/27507190 http://dx.doi.org/10.18632/oncotarget.9552 |
Ejemplares similares
-
The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
por: Amirouchene-Angelozzi, Nabil, et al.
Publicado: (2016) -
Selumetinib-based therapy in uveal melanoma patient-derived xenografts
por: Decaudin, Didier, et al.
Publicado: (2018) -
FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma
por: Tarin, Malcy, et al.
Publicado: (2023) -
PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma
por: de Koning, Leanne, et al.
Publicado: (2019) -
Upcoming translational challenges for uveal melanoma
por: Nabil, Amirouchene-Angelozzi, et al.
Publicado: (2015)